Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143134 | 0.95 | TRIM24 (0.36) | TRIM24TRIM33ALDH1A1KMT2AMEN1 | |
| SCHEMBL46361 | 0.90 | KMT2A (0.34) | TRIM24TRIM33ALDH1A1KMT2AMEN1 | |
| Water SCHEMBL31387323 | 0.87 | ALDH1A1 (0.33) | TRIM24TRIM33ALDH1A1KMT2AMEN1 | |
| SCHEMBL13276962 | 0.86 | TRIM24 (0.39) | TRIM24TRIM33ALDH1A1KMT2AMEN1 | |
| SCHEMBL14506033 | 0.83 | TRIM24 (0.41) | TRIM24TRIM33ALDH1A1KDM4EPOLB | |
| SCHEMBL8603903 | 0.82 | ALDH1A1 (0.46) | TRIM24TRIM33ALDH1A1KMT2AMEN1 | |
| SCHEMBL7523454 | 0.81 | GAA (0.32) | — | |
| SCHEMBL31715737 | 0.81 | GAA (0.33) | ALDH1A1KMT2AMEN1CYP2C9KDM4E | |
| SCHEMBL12350017 | 0.80 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1KMT2AMEN1 | |
| SCHEMBL13500408 | 0.79 | MEN1 (0.34) | TRIM24TRIM33ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4294761-A | Preparation of 7,12-dioxaspiro[5,6]dodecane-3-one | EASTMAN KODAK COMPANY (US) | 1981-10-13 | — | — | US | claimed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| WO-2010121963-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-10-28 | — | — | WO | disclosed |
| US-4721725-A | Aryl-cycloalkyl[b]pyrrole derivatives | E. R. SQUIBB & SONS, INC. (US) | 1988-01-26 | — | — | US | disclosed |
| US-4294761-A | Preparation of 7,12-dioxaspiro[5,6]dodecane-3-one | EASTMAN KODAK COMPANY (US) | 1981-10-13 | — | — | US | disclosed |
| US-4294761-A | Preparation of 7,12-dioxaspiro[5,6]dodecane-3-one | EASTMAN KODAK COMPANY (US) | 1981-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | TRIM24 1665/4885TRIM33 847/4885ALDH1A1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.